Evolent Health, Inc.
EVH NYSE· Services-Management Services
Last close · Oct 23, 2026
$4.80
KIRA · Stoqly’s AI analyst, in plain words
- Evolent Health, Inc. had $1.9B of revenue in fiscal 2025, down 26.6% on the year before. Over five years, revenue changed +15.2% a year on average.
- Its operating margin was −21.9%, down 20.3 pts: of every 100 in sales, about −22 is left after running the business.
- Evolent Health, Inc. lost $535M in fiscal 2025.
- Evolent Health, Inc. returned $40.0M to shareholders in fiscal 2025. The diluted share count fell 0.4%.
- Evolent Health, Inc. owes $819M more than it holds in cash.
Market cap
$540M
P/E
—
Revenue
$1.9B
Net income
−$535M
Free cash flow
—
Operating margin
−21.9%
Evolent Health, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−26.6%
No. Sales fell 26.6% last year.
Does it make a profit?
−28.5%
No. It lost money last year.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Evolent Health, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Evolent Health, Inc.
- CIK
- 0001628908
Evolent Health, Inc. · EVH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $908M | $1.4B | $2.0B | $2.6B | $1.9B |
| Revenue growth | −1.8% | 48.9% | 45.3% | 30.1% | −26.6% |
| Gross margin | 27.6% | 23.4% | 23.4% | 14.4% | 21.3% |
| Operating margin | −4.7% | 0.3% | −3.6% | −1.6% | −21.9% |
| Net income | −$37.6M | −$19.2M | −$113M | −$61.6M | −$535M |
| Net margin | −4.1% | −1.4% | −5.8% | −2.4% | −28.5% |
| Diluted EPS | −$0.44 | −$0.20 | −$1.28 | −$0.81 | −$5.07 |
| Cash | |||||
| Cash from operations | $38.7M | −$11.6M | $143M | $18.8M | $38.8M |
| Share buybacks | — | — | $0.0M | $0.0M | $40.0M |
| Share count change | 1.3% | 8.9% | 18.7% | 3.1% | −0.4% |
| Debt and strength | |||||
| Cash and short-term investments | $266M | $188M | $193M | $104M | $152M |
| Debt incl. finance leases | $216M | $413M | $597M | $662M | $971M |
| Shareholders' equity | $694M | $859M | $1.1B | $1.0B | $415M |
| Net debt / EBITDA | −2.9x | 3.2x | 7.7x | 7.2x | — |
| Current ratio | 1.2x | 1.1x | 1.0x | 0.8x | 1.3x |
| Interest coverage | −1.7x | 0.2x | −1.3x | −1.6x | −7.1x |
| Returns and quality | |||||
| Return on capital | −5.2% | 0.3% | −3.8% | −2.1% | −26.3% |
| Return on equity | −5.7% | −2.5% | −11.7% | −6.0% | −75.5% |
| Piotroski F-score | 4 | 3 | 4 | 4 | 5 |
| Altman Z'' | −0.3 | 0.0 | −0.2 | −0.6 | −3.0 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.3M
1 insider
Of sales under plans
100%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evolent Health, Inc. · EVH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.80 a share, the company is worth $540M.
Source: SEC EDGAR XBRL filings (CIK 0001628908). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.